Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

NCT03654716 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators